In patients with metastatic RCC who have had a complete response to pembrolizumab and axitinib and undergone a nephrectomy, how long would you continue therapy post-operatively?

This is a great question and increasingly relevant. The larger question is about duration of IO-based therapy in general, especially when patients are at maximal response (CR or deep and stable PRs). The honest answer is that nobody knows. My sense is that the decision is based on pt preference and ...